JP2013527772A - 急性期ケア環境においてリポタンパク質関連ホスホリパーゼａ２を使用する方法 - Google Patents

急性期ケア環境においてリポタンパク質関連ホスホリパーゼａ２を使用する方法 Download PDF

Info

Publication number
JP2013527772A
JP2013527772A JP2013510163A JP2013510163A JP2013527772A JP 2013527772 A JP2013527772 A JP 2013527772A JP 2013510163 A JP2013510163 A JP 2013510163A JP 2013510163 A JP2013510163 A JP 2013510163A JP 2013527772 A JP2013527772 A JP 2013527772A
Authority
JP
Japan
Prior art keywords
pla2
stroke
subject
tia
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013510163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013527772A5 (enExample
Inventor
モンターナー，ホアン
マルティネス，マリア，ピラール デルガード
Original Assignee
ディアデクサス インコーポレーテッド
フンダシオ インスティトゥト デ レセルカ デ ロスピタル ウニヴェルシタリ ヴァル デブロン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディアデクサス インコーポレーテッド, フンダシオ インスティトゥト デ レセルカ デ ロスピタル ウニヴェルシタリ ヴァル デブロン filed Critical ディアデクサス インコーポレーテッド
Publication of JP2013527772A publication Critical patent/JP2013527772A/ja
Publication of JP2013527772A5 publication Critical patent/JP2013527772A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/02007—Evaluating blood vessel condition, e.g. elasticity, compliance
    • A61B5/02014—Determining aneurysm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/08—Clinical applications
    • A61B8/0891—Clinical applications for diagnosis of blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/48—Diagnostic techniques
    • A61B8/488—Diagnostic techniques involving Doppler signals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)
    • G01N2333/92—Triglyceride splitting, e.g. by means of lipase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
JP2013510163A 2010-04-30 2011-05-02 急性期ケア環境においてリポタンパク質関連ホスホリパーゼａ２を使用する方法 Pending JP2013527772A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33019310P 2010-04-30 2010-04-30
US61/330,193 2010-04-30
PCT/US2011/034728 WO2011137419A1 (en) 2010-04-30 2011-05-02 Methods using lipoprotein-associated phospholipase a2 in an acute care setting

Publications (2)

Publication Number Publication Date
JP2013527772A true JP2013527772A (ja) 2013-07-04
JP2013527772A5 JP2013527772A5 (enExample) 2014-08-14

Family

ID=44861949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013510163A Pending JP2013527772A (ja) 2010-04-30 2011-05-02 急性期ケア環境においてリポタンパク質関連ホスホリパーゼａ２を使用する方法

Country Status (6)

Country Link
US (1) US20130236450A1 (enExample)
EP (1) EP2563914A4 (enExample)
JP (1) JP2013527772A (enExample)
CN (1) CN103124785A (enExample)
CA (1) CA2798122A1 (enExample)
WO (1) WO2011137419A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160015526A (ko) * 2014-07-30 2016-02-15 경희대학교 산학협력단 부작용이 억제된 암치료용 약학 조성물

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070166777A1 (en) 2004-04-16 2007-07-19 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
WO2015123598A1 (en) * 2014-02-14 2015-08-20 Diadexus, Inc. Biomarkers for cardiovascular disease
WO2017221795A1 (ja) 2016-06-22 2017-12-28 旭化成ファーマ株式会社 Ｌｐ－ＰＬＡ２活性の測定

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089184A2 (en) * 2003-04-01 2004-10-21 Diadexus, Inc. NEW USES OF Lp-PLA2 IN COMBINATION TO ASSESS CORONARY RISK

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6161547A (en) * 1999-01-15 2000-12-19 Coaxia, Inc. Medical device for flow augmentation in patients with occlusive cerebrovascular disease and methods of use
AU2003902115A0 (en) * 2003-05-02 2003-05-22 The University Of Queensland Method of predicting functional outcome of a stroke using eeg measures
WO2005116268A2 (en) * 2004-05-27 2005-12-08 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Differential expression of molecules associated with acute stroke
EP2166358A1 (en) * 2008-09-17 2010-03-24 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Differential diagnostic biomarkers of stroke mimicking conditions and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089184A2 (en) * 2003-04-01 2004-10-21 Diadexus, Inc. NEW USES OF Lp-PLA2 IN COMBINATION TO ASSESS CORONARY RISK

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6015027706; ＭＯＣＫＥＬ，　Ｍ．　ｅｔ　ａｌ．: '"Ｄｅｖｅｌｏｐｍｅｎｔ　ｏｆ　ａｎ　ｏｐｔｉｍｉｚｅｄ　ｍｕｌｔｉｍａｒｋｅｒ　ｓｔｒａｔｅｇｙ　ｆｏｒ　ｅａｒｌｙ　ｒｉｓｋ　ａｓｓｅｓｓｍｅｎｔ　ｏｆ　ｐａｔｉｅｎｔｓ　ｗｉｔｈ　ａｃｕｔｅ　ｃ' ＣＬＩＮ．　ＣＨＩＭ．　ＡＣＴＡ Ｖｏｌ．３９３，　Ｎｏ．２, 20080717, ｐｐ．１０３-１０９ *
JPN6015027708; Ｏ'ＤＯＮＯＧＨＵＥ，　Ｍ．　ｅｔ　ａｌ．: '"Ｌｉｐｏｐｒｏｔｅｉｎ-ａｓｓｏｃｉａｔｅｄ　ｐｈｏｓｐｈｏｌｉｐａｓｅ　Ａ２　ａｎｄ　ｉｔｓ　ａｓｓｏｃｉａｔｉｏｎ　ｗｉｔｈ　ｃａｒｄｉｏｖａｓｃｕｌａｒ　ｏｕｔｃｏｍｅｓ　ｉｎ　ｐａｔｉｅｎｔ' ＣＩＲＣＵＬＡＴＩＯＮ Ｖｏｌ．１１３，　Ｎｏ．１４, 20060411, ｐｐ．１７４５-１７５２ *
JPN6015027709; ＣＵＣＣＩＡＲＡ，　Ｂ．Ｌ．　ｅｔ　ａｌ．: '"Ｌｉｐｏｐｒｏｔｅｉｎ-ａｓｓｏｃｉａｔｅｄ　ｐｈｏｓｐｈｏｌｉｐａｓｅ　Ａ２　ａｎｄ　Ｃ-ｒｅａｃｔｉｖｅ　ｐｒｏｔｅｉｎ　ｆｏｒ　ｒｉｓｋ-ｓｔｒａｔｉｆｉｃａｔｉｏｎ　ｏｆ　ｐａｔｉｅｎｔｓ' ＳＴＲＯＫＥ Ｖｏｌ．４０，　Ｎｏ．７, 200907, ｐｐ．２３３２-２３３６ *
JPN6015027710; ＧＯＲＥＬＩＣＫ，　Ｐ．Ｂ．　ｅｔ　ａｌ．: '"Ｌｉｐｏｐｒｏｔｅｉｎ-ａｓｓｏｃｉａｔｅｄ　ｐｈｏｓｐｈｏｌｉｐａｓｅ　Ａ２　ａｎｄ　ｒｉｓｋ　ｏｆ　ｓｔｒｏｋｅ．"' ＡＭ．　Ｊ．　ＣＡＲＤＩＯＬ． Ｖｏｌ．１０１，　Ｎｏ．１２Ａ, 20080616, ｐｐ．３４Ｆ-４０Ｆ *
JPN6015027713; ＴＨＥ　ＮＡＴＩＯＮＡＬ　ＩＮＳＴＩＴＵＴＥ　ＯＦ　ＮＥＵＲＯＬＯＧＩＣＡＬ　ＤＩＳＯＲＤＥＲＳ　ＡＮＤ　ＳＴＲＯＫＥ　ｒｔ-ＰＡ　ＳＴＲＯＫＥ　ＳＴＵＤＹ　ＧＲＯＵＰ: '"Ｔｉｓｓｕｅ　ｐｌａｓｍｉｎｏｇｅｎ　ａｃｔｉｖａｔｏｒ　ｆｏｒ　ａｃｕｔｅ　ｉｓｃｈｅｍｉｃ　ｓｔｒｏｋｅ．　Ｔｈｅ　Ｎａｔｉｏｎａｌ　Ｉｎｓｔｉｔｕｔｅ　ｏｆ　Ｎｅｕｒｏｌｏｇｉｃａｌ　Ｄｉｓｏ' Ｎ．　ＥＮＧ．　Ｊ．　ＭＥＤ． Ｖｏｌ．３３３，　Ｎｏ．２４, 19951214, ｐｐ．１５８１-１５８７ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160015526A (ko) * 2014-07-30 2016-02-15 경희대학교 산학협력단 부작용이 억제된 암치료용 약학 조성물
KR101629560B1 (ko) 2014-07-30 2016-06-13 경희대학교 산학협력단 부작용이 억제된 암치료용 약학 조성물

Also Published As

Publication number Publication date
WO2011137419A1 (en) 2011-11-03
CA2798122A1 (en) 2011-11-03
CN103124785A (zh) 2013-05-29
EP2563914A4 (en) 2013-11-20
US20130236450A1 (en) 2013-09-12
EP2563914A1 (en) 2013-03-06
WO2011137419A8 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
Eder et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study.
Blake et al. Inflammatory bio‐markers and cardiovascular risk prediction
Dessein et al. Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis.
Vlachopoulos et al. Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease
Satoh et al. Plasma cyclophilin A is a novel biomarker for coronary artery disease
Wong et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation
Colley et al. Lipoprotein associated phospholipase A2: role in atherosclerosis and utility as a biomarker for cardiovascular risk
Purroy et al. C‐reactive protein predicts further ischemic events in transient ischemic attack patients
Kjaergaard et al. Elevated plasma YKL‐40 levels and ischemic stroke in the general population
Kadoglou et al. Adipokines: a novel link between adiposity and carotid plaque vulnerability
Wang et al. Increased serum level of growth differentiation factor 15 (GDF‐15) is associated with coronary artery disease
JP2013527772A (ja) 急性期ケア環境においてリポタンパク質関連ホスホリパーゼａ２を使用する方法
Donate-Correa et al. Klotho as a biomarker of subclinical atherosclerosis in patients with moderate to severe chronic kidney disease
Sverdlov et al. Determinants of aortic sclerosis progression: implications regarding impairment of nitric oxide signalling and potential therapeutics
Kaski et al. Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome
Jylhävä et al. Pentraxin 3 (PTX3) is associated with cardiovascular risk factors: the Health 2000 Survey
RU2582291C1 (ru) Способ прогнозирования риска развития неблагоприятных сердечно-сосудистых событий у больных ишемической болезнью сердца с сахарным диабетом 2 типа, перенесших стентирование коронарных артерий
Avci et al. The prognostic utility of plasma NGAL levels in ST segment elevation in myocardial infarction patients
Matsushita et al. Impact of serum lipoprotein (a) level on coronary plaque progression and cardiovascular events in statin-treated patients with acute coronary syndrome: a yokohama-acs substudy
Massot et al. Lipoprotein-associated phospholipase A2 testing usefulness among patients with symptomatic intracranial atherosclerotic disease
Miura et al. Prognostic value of plasma von Willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease
Khakpour et al. Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy
Tan et al. Low plasma uromodulin is a predictor of early stage chronic kidney disease progression
Jensen-Urstad et al. Cardiac valvular abnormalities are frequent in systemic lupus erythematosus patients with manifest arterial disease
Maksimovic et al. Relationship between peripheral arterial disease and metabolic syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150708

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151210